Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea

This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat Chronic Migraine in clinical practice.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Migraine Disorders Brain Diseases Central Nervous System Diseases Headache Headache Disorders Headache Disorders, Primary Nervous System Diseases Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients treated with botulinum toxin Type A for chronic migraine in clinical practice.

Exclusion criteria

None.

Treatment and study plan

Botulinum toxin type A

Biological

Botulinum toxin Type A treatment for chronic migraine as per local standard of care in clinical practice.

Primary outcomes

Number of Participants with Adverse Events and Adverse Drug Reactions

Time frame: 4 Years
Headache Impact Test-6 (HIT-6) Score Using a 5-Point Scale

Time frame: 4 Years

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Registry information

Important dates

Study start: 2012
Primary completion: 2015
Study completion: 2015
First posted: Nov 6, 2013
Registry last updated: Apr 8, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed